CSF Levels of the Endocannabinoid Anandamide are Reduced in Patients with Untreated Narcolepsy Type 1: A Pilot Study.
Romigi A, Bari M, Liguori C, Izzi F, Rapino C, Nuccetelli M, Battista N, Bernardini S, Centonze D, Mercuri NB, Placidi F, Maccarrone M.
Romigi A, et al. Among authors: maccarrone m.
CNS Neurol Disord Drug Targets. 2020;19(2):142-147. doi: 10.2174/1871527319666200309115602.
CNS Neurol Disord Drug Targets. 2020.
PMID: 32148204